1177.HKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 17:08):

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...

Stats
本日の出来高	39.49M
平均出来高	52.37M
時価総額	50.97B
EPS	HKD0 ( 2024-03-29 )
次の収益日	( HKD0 ) 2024-06-14
Last Dividend	HKD0.0600 ( 2023-06-20 )
Next Dividend	HKD0 ( N/A )
P/E	25.18
ATR14	HKD0.00800 (0.29%)

ボリューム相関

長: 0.02 (neutral)

短: 0.62 (weak)

Signal:(41.732) Neutral

Sino Biopharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sino Biopharmaceutical 相関 - 通貨/商品

-0.69
( moderate negative )

-0.72
( moderate negative )

0.00
( neutral )

0.58
( weak )

Sino Biopharmaceutical 財務諸表

Annual	2023
収益:	HKD26.20B
総利益:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2023
収益:	HKD26.20B
総利益:	HKD21.21B (80.95 %)
EPS:	HKD0.0997

FY	2022
収益:	HKD28.78B
総利益:	HKD22.98B (79.86 %)
EPS:	HKD0.270

FY	2021
収益:	HKD26.86B
総利益:	HKD21.53B (80.15 %)
EPS:	HKD0.780

Financial Reports:

No articles found.

Sino Biopharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.0600 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Sino Biopharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.59 - good (95.94%) | Divividend Growth Potential Score: 5.14 - Stable (2.85%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.00198	2004-09-16
Last Dividend	HKD0.0600	2023-06-20
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	70	--
Total Paid Out	HKD0.573	--
Avg. Dividend % Per Year	0.00%	--
Score	3.91	--
Div. Sustainability Score	9.59
Div.Growth Potential Score	5.14
Div. Directional Score	7.37	--

Next Divdend (Est)
(2024-08-29)

HKD0 Estimate 4.19 %

Dividend Stability

0.34 Poor

Dividend Score

3.91

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2362.HK	No Dividend Player	2023-06-01	Annually	0.00%
1349.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0393.HK	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%
6677.HK	Ex Dividend Junior	2023-06-01	Annually	0.00%
1899.HK	Ex Dividend Junior	2023-06-13	Annually	0.00%
0927.HK	Ex Dividend Knight	2023-08-29	Semi-Annually	0.00%
0057.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
2883.HK	Ex Dividend Knight	2023-06-07	Annually	0.00%
1480.HK	Ex Dividend Knight	2023-06-08	Sporadic	0.00%
0551.HK	Ex Dividend Junior	2023-09-12	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0711	1.500	8.58	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0247	1.200	9.18	10.00	[0 - 0.3]
returnOnEquityTTM	0.0519	1.500	-0.534	-0.801	[0.1 - 1]
payoutRatioTTM	0.404	-1.000	5.96	-5.96	[0 - 1]
currentRatioTTM	1.053	0.800	9.73	7.79	[1 - 3]
quickRatioTTM	0.755	0.800	-0.263	-0.210	[0.8 - 2.5]
cashRatioTTM	0.418	1.500	8.79	10.00	[0.2 - 2]
debtRatioTTM	0.197	-1.500	6.72	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.142	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.410	-1.500	8.36	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.788	1.000	0.197	0.197	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.94	7.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.306	1.000	9.41	9.41	[0.2 - 2]
assetTurnoverTTM	0.347	0.800	-1.020	-0.816	[0.5 - 2]
Total Score				9.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	31.82	1.000	6.89	0	[1 - 100]
returnOnEquityTTM	0.0519	2.50	-0.343	-0.801	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.142	2.00	9.95	10.00	[0 - 30]
dividendYielPercentageTTM	3.12	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.196	2.00	9.93	10.00	[0 - 30]
payoutRatioTTM	0.404	1.500	5.96	-5.96	[0 - 1]
pegRatioTTM	0.329	1.500	-1.141	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.174	1.000	8.16	0	[0.1 - 0.5]
Total Score				5.14

Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.